Analysts Offer Predictions for Esperion Therapeutics, Inc.’s Q3 2025 Earnings (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPRFree Report) – Stock analysts at Zacks Research lifted their Q3 2025 earnings per share (EPS) estimates for Esperion Therapeutics in a report issued on Monday, June 10th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings of $0.00 per share for the quarter, up from their prior estimate of ($0.01). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.05) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q4 2025 earnings at $0.10 EPS and FY2026 earnings at $0.54 EPS.

Other research analysts have also issued research reports about the company. StockNews.com lowered Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 17th. Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday, May 7th. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research note on Tuesday, May 21st. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Esperion Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $9.33.

View Our Latest Stock Analysis on ESPR

Esperion Therapeutics Price Performance

Shares of ESPR opened at $2.91 on Tuesday. Esperion Therapeutics has a twelve month low of $0.70 and a twelve month high of $3.40. The firm has a fifty day simple moving average of $2.30 and a two-hundred day simple moving average of $2.29.

Esperion Therapeutics (NASDAQ:ESPRGet Free Report) last released its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.34 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.42. The company had revenue of $137.74 million during the quarter, compared to the consensus estimate of $53.11 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bellevue Group AG lifted its position in Esperion Therapeutics by 136.5% during the first quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock valued at $26,650,000 after purchasing an additional 5,739,800 shares during the period. Vanguard Group Inc. grew its stake in shares of Esperion Therapeutics by 71.8% in the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after buying an additional 3,688,796 shares in the last quarter. Armistice Capital LLC bought a new stake in shares of Esperion Therapeutics in the 4th quarter worth about $9,568,000. GSA Capital Partners LLP lifted its holdings in shares of Esperion Therapeutics by 159.1% in the 3rd quarter. GSA Capital Partners LLP now owns 1,116,655 shares of the biopharmaceutical company’s stock worth $1,094,000 after acquiring an additional 685,733 shares during the last quarter. Finally, Wasatch Advisors LP lifted its holdings in Esperion Therapeutics by 2.7% during the 1st quarter. Wasatch Advisors LP now owns 9,129,647 shares of the biopharmaceutical company’s stock valued at $24,467,000 after buying an additional 238,544 shares in the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

(Get Free Report)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Featured Articles

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.